Global Huntington’s Disease Market, By Diagnosis (MRI, CT Scan, Genetic Testing, Others), Treatment Type (Symptomatic Therapy, Disease-Modifying Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Huntington’s Disease Market Analysis and Size
Huntington’s disease affects around 30,000 people in North America, with a prevalence rate of 5.7 per 100,000 people. It is not so common in children. Huntington’s disease is expected to witness extensive developments in the upcoming years as disease-modifying drugs transform the market landscape. Latest research in this condition focuses mainly on using several novel treatments such as immuno-modulating therapies, gene therapy (using antisense oligonucleotides, mRNA splicing, micro RNAs (miRNA), and zinc-finger DNA binding protein (ZFP)).
Data Bridge Market Research analyses a growth rate in Huntington’s disease market in the forecast period 2023-2030. The expected CAGR of Huntington’s disease market is tend to be around 20.1% in the mentioned forecast period. The market was valued at USD 434.7 million in 2022, and it would grow upto USD 1881.63 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Huntington’s Disease Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (MRI, CT Scan, Genetic Testing, Others), Treatment Type (Symptomatic Therapy, Disease-Modifying Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Amneal Pharmaceuticals LLC. (U.S.), Elekta AB (Sweden), Alnylam Pharmaceuticals, Inc (U.S.), Apotex Inc (Canada), Armata Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), H. Lundbeck A/S (Denmark), Alterity Therapeutics (Australia), Vertex Pharmaceuticals Incorporated (U.S.), SK Plc. (U.K.), Ceregene, Inc (U.S.), SOM BIOTECH (Spain), Palobiofarma (Spain), and Ipsen Pharma (France)
|
|
Market Opportunities
|
|
Market Definition
Huntington’s disease is a rare type of inherited disease which causes progressive breakdown of nerve cells in the brain, majorly affecting physical movements, emotions and cognitive abilities. The symptoms associated with this disease can appear at any time but typically appear at 30-40 years old. If the condition appears before 20 years of age, this disorder is considered to be juvenile Huntington’s disease.
Huntington’s Disease Market Dynamics
Drivers
- Increasing Prevalence of Huntington’s Disease
Huntington’s Disease (HD) is a progressive neurological condition that is caused by CAG expansions in the Huntingtin (Htt) gene. It affects around 1 out of every 10,000 people in the U.S. Healthy people mostly have less than 35 CAG repetitions, on the other hand, HD patients have CAG expansions that ranges from 36 to 200. The frequency varies by more than 10-fold between different geographical locations, that can be associated to variations in case ascertainment and diagnostic criteria.
- Growing Demand For Disease-Modifying Therapies
The disease-modifying therapies segment is projected to witness the huge growth during the forecast period. This is due to an increase in R&D for disease-modifying therapy and the rising demand for advanced products, such as gene therapy and stem cell therapy. The government initiatives such as Fast Track Designation by the U.S. FDA for increasing the registration process may surge the market in the upcoming years. For instance, in 2021 in the month of September, U.S. FDA granted fast track designation to Sage Therapeutics’s drug, SAGE-718, as a budding treatment for Huntington’s disease.
Opportunities
- Increased Clinical Research Activities
There have been growing clinical research activities for numerous drug development processes that are boosting the market's growth. For instance, Annexon, Inc. is engaged in the development of ANX005-an experimental monoclonal antibody that targets abnormal C1q activity in complement-mediated neurodegenerative diseases, such as huntington’s disease. This is administered intravenously (IV) and is meant to suppress C1q. Additionally, in November 2020, the company initiated a phase 2 clinical trial of ANX005 used for the treatment of HD patients. Stem cell therapy is also causing interest as a potential treatment for HD. Cellavita, in collaboration with AzidusPharma, is currently investigating stem cell therapy, CELLAVITA-HD in phase 2/ 3 ADORE-DH trial.
- Increasing Drug Approvals
There have been growing drug approvals for the treatment of HD patients. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. received NMPA approval for Austedo in China for treating cholera associated with Huntington’s disease. This huge expansion of the company is anticipated to increase the patient base and the revenue growth.
Restraints/Challenges
- Limited Availability of Drugs
The number of approved drugs for Huntington’s disease are limited because of strict policies and regulations. This is anticipated to impede the market growth during the forecast period. Furthermore, the lack of awareness about this disorder in major parts of the world is estimated to restrict the growth of huntington’s disease market.
- Discontinuation of Drug Trials
The drug development for the disease has faced severe obstacles as several therapies have failed to demonstrate efficacy or were related with major toxicity. For instance, in March 2021, F. Hoffmann-La Roche Ltd. discontinued the dosing in the phase III GENERATION HD1 study of tominersen in manifest HD. This conclusion was made on the basis of findings of an unblinded Independent Data Monitoring Committee's (iDMC) pre planned examination of data from the phase III research.
This Huntington’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Huntington’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Huntington’s Disease Market
During the COVID-19 pandemic, the sales of off-label drugs such as antipsychotics, anti-depressants, and anticonvulsant were done through numerous online pharmacies to manage symptoms associated with the disease. The conduction of clinical trials was delayed because of the government-imposed lockdown during the COVID-19 pandemic.
In the post pandemic era, many of hospitals and clinics worldwide reported that clinical visits frequency for the diagnosis and treatment of HD has improved. Consequently, the market will grow with the projected growth rate. The clinical trials for Huntington’s disease development have increased post-pandemic.
Recent Developments:
- In 2021, NeuExcell Therapeutics Inc collaborated with Spark Therapeutics, Inc. to develop gene therapy for the treatment of HD. Under the agreement, NeuExcell Therapeutics is meant to receive upfront license fees, R&D, and sales milestone payments of up to approximately USD 190 million and additional product royalties.
Global Huntington’s Disease Market Scope
The Huntington’s disease market is segmented on the basis of diagnosis, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- MRI
- CT Scan
- Genetic Testing
- Others
Treatment Type
- Symptomatic Therapy
- Disease-Modifying Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Huntington’s Disease Market Regional Analysis/Insights
The Huntington’s disease market is analyzed and market size insights and trends are provided by diagnosis, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the Huntington’s disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for Huntington’s disease market throughout the forecasted period due to the continuously increasing population resulting increasing prevalence of CNS related disorders.
North America dominates the market due to increased demand of CNS disorders treatment and research undertaken by several companies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Huntington’s Disease Market Share Analysis
The Huntington’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Huntington’s disease market.
Key players operating in the Huntington’s disease market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Amneal Pharmaceuticals LLC. (U.S.)
- Elekta AB (Sweden)
- Alnylam Pharmaceuticals, Inc (U.S.)
- Apotex Inc (Canada)
- Armata Pharmaceuticals, Inc. (U.S.)
- Pfizer Inc (U.S.)
- H. Lundbeck A/S (Denmark)
- Alterity Therapeutics (Australia)
- Vertex Pharmaceuticals Incorporated (U.S.)
- SK Plc. (U.K.)
- Ceregene, Inc (U.S.)
- SOM BIOTECH (Spain)
- Palobiofarma (Spain)
- Ipsen Pharma (France)
SKU-